Qualigen Therapeutics Inc (QLGN) - Total Liabilities
Based on the latest financial reports, Qualigen Therapeutics Inc (QLGN) has total liabilities worth $4.92 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Qualigen Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Qualigen Therapeutics Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Qualigen Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Qualigen Therapeutics Inc (QLGN) total assets.
Qualigen Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Qualigen Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kia Lim Bhd
KLSE:6211
|
Malaysia | RM24.19 Million |
|
C&C Group plc
LSE:CCR
|
UK | GBX812.48 Million |
|
Helios Energy Ltd
AU:HE8
|
Australia | AU$1.91 Million |
|
MRG Metals Ltd
AU:MRQ
|
Australia | AU$182.35K |
|
Eminence Minerals Limited
AU:EMA
|
Australia | AU$486.44K |
|
ADCORE INC. O.N.
F:ADQ
|
Germany | €5.45 Million |
|
CN Asia Corporation Bhd
KLSE:7986
|
Malaysia | RM17.69 Million |
|
METALQUEST MINING INC.
F:E7Q
|
Germany | €139.10K |
Liability Composition Analysis (2012–2024)
This chart breaks down Qualigen Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Qualigen Therapeutics Inc (QLGN) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Qualigen Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Qualigen Therapeutics Inc (2012–2024)
The table below shows the annual total liabilities of Qualigen Therapeutics Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.01 Million | -51.47% |
| 2023-12-31 | $4.14 Million | -59.90% |
| 2022-12-31 | $10.32 Million | +64.52% |
| 2021-12-31 | $6.27 Million | -42.11% |
| 2020-12-31 | $10.83 Million | +538.30% |
| 2019-12-31 | $1.70 Million | -71.40% |
| 2018-12-31 | $5.93 Million | +119.14% |
| 2017-12-31 | $2.71 Million | -13.60% |
| 2016-12-31 | $3.13 Million | +131.33% |
| 2015-12-31 | $1.35 Million | +7.97% |
| 2014-12-31 | $1.25 Million | +39.73% |
| 2013-12-31 | $897.96K | -1.38% |
| 2012-12-31 | $910.48K | -- |
About Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS tha… Read more